NCT07129343View on ClinicalTrials.gov

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 12, 2025

Primary Completion Date

November 25, 2027

Study Completion Date

November 25, 2027

Conditions
Von Willebrand Disease (VWD)
Interventions
BIOLOGICAL

VONVENDI

VONVENDI is administered by intravenous injection.

BIOLOGICAL

ADVATE

ADVATE is administered by intravenous injection.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY